FDA panel to review Theravance, J&J antibiotics in February

01/10/2008 | Forbes · Forbes

A panel of antibiotic experts appointed by the FDA will meet Feb. 27 to review Theravance's injectable antibiotic telavancin for the treatment of skin infections caused by "superbug" bacteria. The next day, the panel will consider the approval of Johnson & Johnson's antibiotic for diabetes-related foot infections, the agency announced.

View Full Article in:

Forbes · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN